MSLN and neoplasm: These data areencouraging for the continued development and translation of antibodydomains for use as targeted PET-imaging agents for MSLN-positive cancers.In addition, the in vivo assessment of distributionsand tumor penetrations of high affinity anti-MSLN antibody domainsthrough PET-imaging will help guide designs of antibody domain-basedchemotherapeutic drug conjugates for treatment of MSLN-expressingcancers.